Celdara Medical, LLC

Celdara Medical, LLC, a self-certified small disadvantaged business and limited liability company based in Lebanon, New Hampshire, develops cell-based and protein-engineering therapeutics for cancer immunotherapy, neurological disorders, viral diseases, and metabolic conditions, and operates exclusively as a prime recipient on federal research grants while holding a single full-and-open federal services contract with the Small Business Administration.

Celdara's federal footprint is dominated by biomedical research grants from the National Institutes of Health and allied agencies. The vendor is a recipient on eleven awards from the National Institute of Allergy and Infectious Diseases (combined potential value $1.8 million), five awards from the National Cancer Institute, four awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and two awards from the National Center for Advancing Translational Sciences (combined potential value $1.5 million). Representative grant work includes a $310,564 Project Grant from NCATS (CFDA 93.350) for engineered regulatory T cells (Tregs) to address Gaucher syndrome through direct enzyme replacement therapy to the brain and peripheral tissues, a $450,000-range Project Grant from the National Cancer Institute for development of CM-HZ01, a non-alpha IL-2 super-agonist for metastatic melanoma, and a $270,000-range Project Grant from the National Institute of Neurological Disorders and Stroke for CM-EA1, a neuroprotective therapeutic targeting acute ischemic stroke. Additional grant work spans antimicrobial peptide development for multidrug-resistant bacterial infections (National Heart Lung and Blood Institute), CAR T-cell platforms for solid tumors (National Cancer Institute), ALS therapies (National Institute of Neurological Disorders and Stroke), type 2 diabetes interventions (National Institute of Diabetes and Digestive and Kidney Diseases), pandemic influenza countermeasures (National Institute of Allergy and Infectious Diseases), and a fellowship program for biotech entrepreneurship in Alzheimer's disease (National Institute on Aging).

Celdara's sole federal services contract—a $2.6 million firm-fixed-price award from the SBA's Office of Investments and Innovations, announced September 2024 with ultimate completion May 2025—provides regional innovation cluster services to support small businesses in advanced computing, biotechnology, clean energy, and cybersecurity sectors. This contract was competitively awarded under full and open solicitation (Solicitation 73351024R0007) for a base period of twelve months plus four 12-month option years.

Activity has declined sharply in recent years. The vendor received five awards in 2022, two in 2023, and one award each in 2024, 2025, and 2026 respectively. The portfolio shows 47 prime awards with combined potential value of $6.2 million, though obligated dollars across all awards total $73.7 million—a signal of substantial completed and invoiced work. Four awards face ultimate completion within the next twenty-four months and present recompete exposure. Celdara operates exclusively as a prime, with no subcontractor awards recorded in the portfolio.

Service Contract Inventory data capture only the SBA regional innovation cluster contract and related prime work above the $150,000 reporting threshold. SCI-reportable invoiced revenue totaled $1.1 million in FY2022 across 2.6 FTEs, with no SCI-captured invoicing in FY2023 or FY2024. Government-paid hourly rates on SCI-reportable prime records ran a median of $201.21 per hour, with rates ranging from the 10th percentile at $188.23 per hour to the 90th percentile at $214.19 per hour. Across prime contracts, subcontractors performed approximately 7 percent of total contractor hours, with one named subcontractor reported across the SCI dataset. These figures represent a partial view of Celdara's federal services activity and exclude the grant portfolio, goods, and non-federal revenue.